GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Cyclically Adjusted PS Ratio

H. Lundbeck AS (OCSE:HLUN A) Cyclically Adjusted PS Ratio : 0.43 (As of Jul. 16, 2025)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Cyclically Adjusted PS Ratio?

As of today (2025-07-16), H. Lundbeck AS's current share price is kr29.40. H. Lundbeck AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr68.45. H. Lundbeck AS's Cyclically Adjusted PS Ratio for today is 0.43.

The historical rank and industry rank for H. Lundbeck AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCSE:HLUN A' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.27   Med: 0.41   Max: 0.57
Current: 0.44

During the past years, H. Lundbeck AS's highest Cyclically Adjusted PS Ratio was 0.57. The lowest was 0.27. And the median was 0.41.

OCSE:HLUN A's Cyclically Adjusted PS Ratio is ranked better than
88.33% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.2 vs OCSE:HLUN A: 0.44

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

H. Lundbeck AS's adjusted revenue per share data for the three months ended in Mar. 2025 was kr6.286. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr68.45 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


H. Lundbeck AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for H. Lundbeck AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Cyclically Adjusted PS Ratio Chart

H. Lundbeck AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.30 0.39 0.48

H. Lundbeck AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.47 0.52 0.48 0.42

Competitive Comparison of H. Lundbeck AS's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Cyclically Adjusted PS Ratio falls into.


;
;

H. Lundbeck AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

H. Lundbeck AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=29.40/68.45
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, H. Lundbeck AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=6.286/120.2000*120.2000
=6.286

Current CPI (Mar. 2025) = 120.2000.

H. Lundbeck AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 18.449 100.300 22.109
201509 18.624 100.200 22.341
201512 18.917 99.800 22.784
201603 19.089 100.200 22.899
201606 19.002 100.600 22.704
201609 20.000 100.200 23.992
201612 21.420 100.300 25.670
201703 21.343 101.200 25.350
201706 21.653 101.200 25.718
201709 21.915 101.800 25.876
201712 22.393 101.300 26.571
201803 23.075 101.700 27.273
201806 23.669 102.300 27.810
201809 23.305 102.400 27.356
201812 19.885 102.100 23.410
201903 21.309 102.900 24.892
201906 21.369 102.900 24.962
201909 20.810 102.900 24.309
201912 23.863 102.900 27.875
202003 22.958 103.300 26.714
202006 21.982 103.200 25.603
202009 22.461 103.500 26.085
202012 21.501 103.400 24.994
202103 21.505 104.300 24.783
202106 3.987 105.000 4.564
202109 4.040 105.800 4.590
202112 4.080 106.600 4.601
202203 4.401 109.900 4.813
202206 4.519 113.600 4.782
202209 4.733 116.400 4.888
202212 4.714 115.900 4.889
202303 5.080 117.300 5.206
202306 4.938 116.400 5.099
202309 4.981 117.400 5.100
202312 5.018 116.700 5.168
202403 5.330 118.400 5.411
202406 5.524 118.500 5.603
202409 5.744 118.900 5.807
202412 5.590 118.900 5.651
202503 6.286 120.200 6.286

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


H. Lundbeck AS  (OCSE:HLUN A) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


H. Lundbeck AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines